Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Regulatory Routine +

Cannabix Marijuana Breath Test Achieves Major Milestone: Breath Collection Unit Secures UL and CSA Certifications

Cannabix Secures UL/CSA Certs, Clears Path for Gov Tenders Amidst Steady Commercial Rollout

Executive Summary
  • Cannabix Technologies Inc. announced that its Breath Collection Unit (BCU), a core component of the Marijuana Breath Test (MBT) system, has achieved UL and CSA electrical safety certifications.
  • Certifications include UL 61010-1 for the United States and CSA 61010-1-12 for Canada.
  • Testing was conducted at an independent ISO/IEC 17025 accredited laboratory.
  • The milestone facilitates access to regulated markets including law enforcement, government agencies, and industrial workplace safety sectors.
  • This enables participation in formal tender processes and approved vendor lists requiring specific safety standards.
  • CEO Rav Mlait stated this reflects a focus on product safety, quality, and regulatory compliance during phased commercial deployment.
Material Impact
  • Incremental Validation: The certification is a logical progression following the FCC/ISED emissions testing passed in December 2025 and the Commercial Launch announced in March 2026. It validates existing hardware for broader market access rather than introducing new technology.
  • Market Access: While positive, the company has already secured commercial deliveries to industrial clients (Virginia) and clinics (Eastern Canada) since March 2026 without this specific certification explicitly highlighted as a blocker previously. This removes friction for government tenders but does not represent a sudden revenue inflection point.
  • Expectations: Given the phased rollout strategy announced in March, regulatory milestones like UL/CSA were anticipated by investors familiar with hardware compliance requirements. The news confirms execution rather than surprising the market with new upside.
  • Stock Impact: Likely neutral to slightly positive as it reinforces the commercialization timeline but does not materially alter the valuation model compared to previous delivery announcements.
BLO · Price
Company Overview
  • Company: Cannabix Technologies Inc., a Canadian medical device company focused on breath-based drug testing technology.
  • Flagship Project: Marijuana Breath Test (MBT) system.
    • Components: Breath Collection Unit (BCU) hardware and proprietary Breath Cartridges.
    • Function: Detects delta-9 THC in breath within 4 hours of consumption using LC-MS laboratory analysis.
    • Target Markets: Workplace safety, law enforcement, transportation, industrial manufacturing.
  • Secondary Product: BreathLogix Alcohol Screening Devices (unmanned alcohol testing).
  • Technology Status: Patent granted for Contact-Free Breath Analysis (Oct 2025); FCC/ISED compliance passed (Dec 2025); UL/CSA certification achieved (May 2026).
Read the original news release →

More from Cannabix Technologies Inc.